{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:44:40Z","timestamp":1764585880471,"version":"3.46.0"},"reference-count":10,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Filgrastim is administered to shorten the duration of chemotherapy\u2010induced neutropenia. Filgrastim can be administered intravenously or subcutaneously, but different routes of administration may result in different pharmacokinetic properties, which may affect efficacy. The primary objective of this study was to determine if subcutaneous (SQ) filgrastim would be associated with a shorter time to neutrophil recovery in patients with myeloma undergoing autologous hematopoietic stem cell transplantation (autoHSCT) when compared to intravenous piggyback (IVPB) filgrastim.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single\u2010center, retrospective cohort study of patients undergoing autoHSCT for myeloma admitted and discharged between 2018 and 2019. The primary outcome was the mean number of days from transplant day 0 to absolute neutrophil count (ANC) greater than 500 cells\/\u03bcL. Secondary outcomes were the incidence of and mean number of days of gram\u2010negative antibiotic treatment and 30\u2010day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 196 patients with myeloma met the inclusion criteria. No significant differences in time to neutrophil recovery between IVPB and SQ filgrastim were observed (11.0\u2009\u00b1\u20090.7\u2009days vs. 10.8\u2009\u00b1\u20090.8\u2009days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.15, respectively). No significant differences were observed in any of the secondary outcomes between IVPB and SQ filgrastim.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with myeloma undergoing autoHSCT, no differences in time to neutrophil recovery, incidence of or duration of gram\u2010negative antibiotic treatment, or 30\u2010day mortality were observed between IVPB and SQ routes of filgrastim administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70067","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:39:16Z","timestamp":1762904356000},"page":"741-745","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Subcutaneous Versus Intravenous Filgrastim in Autologous Hematopoietic Stem Cell Transplantation: A Retrospective Study"],"prefix":"10.1002","volume":"45","author":[{"given":"Glenn","family":"Chang","sequence":"first","affiliation":[{"name":"College of Pharmacy Western University of Health Sciences  Pomona California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelina","family":"Nguyen","sequence":"additional","affiliation":[{"name":"College of Pharmacy Western University of Health Sciences  Pomona California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvis","family":"Sampson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services City of Hope National Medical Center \u2013 Upland  Upland California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2751-2597","authenticated-orcid":false,"given":"Doreen","family":"Pon","sequence":"additional","affiliation":[{"name":"College of Pharmacy Western University of Health Sciences  Pomona California USA"},{"name":"Department of Pharmacy Services City of Hope National Medical Center  Duarte California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Amgen Inc \u201cNeupogen (Filgrastim) Injection: HIGHLIGHTS of Prescribing Information \u201d(2023) https:\/\/www.pi.amgen.com\/\u2010\/media\/Project\/Amgen\/Repository\/pi\u2010amgen\u2010com\/neupogen\/neupogen_pi_hcp_english.pdf."},{"key":"e_1_2_11_3_1","unstructured":"National Comprehensive Cancer Network \u201cHematopoietic Growth Factors (Version 2.2023) \u201dhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.20.684"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)21074-6"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/11318090-000000000-00000"},{"issue":"4","key":"e_1_2_11_8_1","first-page":"273","article-title":"Comparison of Intravenous Versus Subcutaneous Recombinant Human Granulocyte\u2010Macrophage Colony\u2010Stimulating Factor in Patients With Primary Myelodysplasia","volume":"19","author":"Rosenfeld C. S.","year":"1991","journal-title":"Experimental Hematology"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23622"},{"issue":"1","key":"e_1_2_11_10_1","first-page":"13","article-title":"Subcutaneous Versus Intravenous Granulocyte Colony\u2010Stimulating Factor to Enhance Neutrophil Engraftment in Patients Undergoing Hematopoietic Stem\u2010Cell Transplant","volume":"10","author":"Ellingson S. L.","year":"2020","journal-title":"Journal of Hematology Oncology Pharmacy"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0018578718811156"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:41:05Z","timestamp":1764585665000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/phar.70067"],"URL":"https:\/\/doi.org\/10.1002\/phar.70067","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2024-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}